Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights - Takeaways - MDSpire

Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights

  • By

  • Esther Ganelin-Cohen

  • Yair Wexler

  • Sraya Kraus

  • Ayal Rozenberg

  • May 1, 2026

  • 0 min

Share

  • 1

    Cladribine was assessed for safety and clinical outcomes in a cohort of 47 children with pediatric-onset multiple sclerosis.

  • 2

    The study found that cladribine had lower discontinuation rates compared to conventional disease-modifying therapies.

  • 3

    No serious adverse events were reported in the cladribine group, indicating a positive safety profile.

  • 4

    NEDA rates were similar between cladribine and conventional DMT cohorts at Year 1, with varying relapse rates over time.

  • 5

    Cladribine's unique dosing schedule may enhance treatment adherence among pediatric patients with multiple sclerosis.

Original Source(s)

Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights

  • by Esther Ganelin-Cohen, Yair Wexler, Sraya Kraus, Ayal Rozenberg

  • May 1, 2026

Related Content

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study

RSV-infected children with mixed infections: clinical features and early predictive indicators of codetection with Streptococcus pneumoniae and Haemophilus influenzae

Management of Bowel and Standard Urotherapy Approaches in Pediatric Patients with Bladder and Bowel Dysfunction: A Randomized Clinical Trial